Role of Concentration of Biomarkers S100B and NSE in Serum in Mild and Moderate Head Trauma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02988102|
Recruitment Status : Unknown
Verified December 2016 by Dr. Fatos Kelmendi, University Clinical Centre of Kosova.
Recruitment status was: Recruiting
First Posted : December 9, 2016
Last Update Posted : December 9, 2016
In pediatric age groups communication difficulties very sometimes may present further obstacles in obtaining a detailed injury history and early identification of TBI symptoms.
Most emergency management protocols are focused exclusively on the identification of the relatively small number of patients who may require operative intervention, as early surgery is believed to improve outcome.
|Condition or disease||Intervention/treatment|
|Biomarkers||Other: Following S100B and NSE in head trauma|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Role of Concentration of Biomarkers S100B and NSE in Serum in Mild and Moderate Head Trauma Injury in Acute Phase in Relation to Head CT and Post Concusion Syndrome.|
|Study Start Date :||December 2016|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||August 2017|
- Other: Following S100B and NSE in head trauma
Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11Other Name: S100B NSE
- Role of concentration of biomarkers S100B and NSE in serum in mild and moderate head trauma injury in acute phase in relation to head CT and post concusion syndrome. [ Time Frame: 2 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02988102
|Contact: Fatos Kelmendi||+377 44 128 firstname.lastname@example.org|
|Contact: Agon Mekaj, PhD||+377 44 email@example.com|
|Tirana, Kosovo Prishtina, Albania, 10 000|
|Contact: Agon Mekaj, PhD +37744373545 firstname.lastname@example.org|
|Contact: Ridvan Alimehmeti, PhD +355692102140 email@example.com|